In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Heart Failure 2021 and beyond - Optimizing Outcomes in Heart Failure

CRT Online Workshop - 2 afternoon sessions from 14:00 - 17:15 CET

16/09/2021 14:00 17/09/2021 17:15 Europe/Paris Heart Failure 2021 and beyond - Optimizing Outcomes in Heart Failure

Access event page

contact@escardio.org DD/MM/YYYY
Online
event

Summary

Chairpersons: Prof. Ewa Jankowska (Heart Failure Association of the ESC), Prof. John McMurray (ESC),
Dr Claudia Kaiser-Albers (MSD), Dr Tomas Andersson (AstraZeneca)

 



Objectives of the workshop

  • Discuss and align on challenges and opportunities facing the development of new medicines and technologies for heart failure.
  • Identify hurdles of implementation and approaches to overcome them.
  • What needs to be modified/changed/optimized in the development and implementation of the new Guidelines.

Programme

16 September

14:00 - 14:10

Introduction – Goals of the CRT and Objectives of the Workshop

Dr C. Kaiser-Albers

SESSION 1 - GUIDELINES 2021 - WHERE DO WE STAND AND WHAT EVIDENCE DO WE STAND ON? 

Moderated by Prof. E. Jankowska and Dr T. Andersson

14:10 - 14:25

New Guidelines Presentation

Prof. M. Metra (IT) & Prof. T. McDonagh (UK)

14:25 - 14:35

The Concept of a Universal Definition of Heart Failure

Why and What it Means in Practice

A Joint Venture of HFA/HFSA/JHFS Societies

Prof. B. Bozkurt (US)

14:35 - 14:55

Reflections on the Guidelines and How they are Implemented.
How Well Did We Do in the Last Five Years?
Examples of Entresto and ICD/CRT

Prof. J. McMurray & Prof. W. Mullens (BE)

14:55 - 15:05

How do We Improve Implementation of Evidence in Practice?
Perspectives from Outside Western Europe

Dr O. Chioncel (RO)

15:05 - 15:45

Panel Discussion including Academia, Industry, Payers, Regulatory, Patients

All

16:55 – 17:05

Discussion

15:45 - 16:00

Break

16:00 - 17:00

Breakout Sessions : Moderated by Appointed Experts and Discussants
Why is the Uptake of Life-Saving Treatments for HF Still Sub-optimal?

17:00 – 17:15

Summary of Pitches - Wrap-up Day 1 - Outlook to Day 2

Prof. E. Jankowska & Dr C. Kaiser-Albers

 

17 September

14:00-17:30

OPTIMIZING OUTCOMES IN HF

Chaired by Prof. J. Mc Murray and Dr C. Kaiser-Albers

14:00 - 14:15

Summary of Day 1 - Viewpoints from the Breakout Sessions
What Else are the Hot Topics in HF?

Dr C. Kaiser-Albers & Dr T. Andersson

SESSION 2 - OPTIMIZING OUTCOMES IN HF WHAT ELSE?

Moderated by Prof. J. Mc Murray and Dr C. Kaiser-Albers

14:15 - 14:25

What Do We Mean by “HFpEF” in 2021 and How Should It Be Treated?

Prof. S. Solomon (USA)

14:25 - 14:35

Should We Bother About The Treatment Advances: Quality of Life and Functional Capacity?

Prof. A. Coats (UK)

14:35 - 14:45

How do We Measure QoL and Assess Functional Capacity?

Dr L. Hill (UK)

14:45 - 14:55

Patient Perspective: What Matters to Me?
(involve patients who have been participating in the discussion on new 2021 HF guidelines.)

Patient representative (tbc)

14:55 - 15:05

How Can Regulators and Payers Contribute to Optimize Outcomes?
 - The EMA Perspective

EMA Speaker (tbc)

15:05 - 15:15

How Can Regulators and Payers Contribute to Optimize Outcomes?
 - A General Perspective of Payers

Prof. U. Siebert (AT)

15:15 - 15:45

Panel / Moderated Discussion with Panelists and Experts Representing a Geographical Diversity

15:45 - 16:00

Break

SESSION 3 - GOING DIGITAL – WILL IT SHAKE UP EVERYTHING?

Moderated by Prof. M. Cowie (tbc)

16:00 - 17:30

Quick Perspectives on:

16:00 - 16:10

Will Digital Tools Help Patients Better Manage Their Disease? Lifestyle, Treatment, Awareness of Disease Fluctuations

Prof. M. Volterrani (IT)

16:10 - 16:20

Can we capture clinical status, activity levels and treatment adherence remotely?

Prof. F. Koehler (DE)

16:20 - 16:30

Education, Implementation, Adherence, Monitoring and Outcomes: The Digital Future of Cardiology

Dr R. Califf (USA)

16:30 - 16:40

Digital Clinical Trials – Patient Enrollment, Monitoring and Collection of Follow-up Data

Prof. Lars Lund (SE)

16:40 - 17:15

Panel Discussion - Could We Have a Common Digital Platform to Deliver Routine Care and Conduct Clinical Trials?

17:15 - 17:30

Key Take-Home Messages / Recommendations in Preparation of the Publication

Chairpersons